Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03213951 · ClinicalTrials.gov registry record
Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 28
- Enrollment target
NCT03213951 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 28 participants.
The verdict
NCT03213951 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
68Ga-PSMA is a radiopharmaceutical used with PET imaging for the detection of prostate cancer under a compassionate IND in patients who have presented with biochemical failure. In this study, the use of 68Ga-PSMA-11 will be extended to newly diagnosed patients with high risk prostate cancer. Patients enrolled to this study will undergo a 68Ga-PSMA-11 PET/CT or PET/MRI scan for research purposes (in addition to the routine CT or MRI that is routinely done for staging), and a second 68Ga-PSMA-11 administration just prior to surgery for experimental ex-vivo beta probe testing of resected tissue. Immediately following resection of the prostate, the intact tissue will be scanned using a PET camera designed for animal research in order to record the 68Ga-PSMA-11 distribution in the isolated tissue at higher resolution than can be attained using whole-body PET imaging. The experimental beta probe will then be use to measure 68Ga-PSMA-11 counts of the resected tissue.
Interventions
- OTHER Experimental beta probe
- DIAGNOSTIC_TEST PSMA-PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-08-18 |
| Est. Completion | 2019-11-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03213951
The ClinicalTrials.gov registry entry for NCT03213951 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Experimental beta probe is the first listed.
NCT03213951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03213951 about?
NCT03213951 is a clinical study titled "Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions". 68Ga-PSMA is a radiopharmaceutical used with PET imaging for the detection of prostate cancer under a compassionate IND in patients who have presented with biochemical failure. In this study, the use of 68Ga-PSMA-11 will be extended to newly diagnosed patients with high risk prostate cancer. Patient...
What is the current status of trial NCT03213951?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2017-08-18. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT03213951?
The interventions under investigation include: Experimental beta probe (OTHER), PSMA-PET (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03213951?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.